Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
Crossref DOI link: https://doi.org/10.3389/fendo.2020.00250
Published Online: 2020-05-15
Update policy: https://doi.org/10.3389/crossmark-policy
Jähn-Rickert, Katharina
Wölfel, Eva M.
Jobke, Björn
Riedel, Christoph
Hellmich, Maya
Werner, Mathias
McDonald, Michelle M.
Busse, Björn
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
Cancer Institute NSW
Version of Record valid from 2020-05-15